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A B S T R A C T
Purpose
To provide treatment recommendations for men with metastatic castration-resistant prostate
cancer (CRPC).
Methods
The American Society of Clinical Oncology and Cancer Care Ontario convened an expert panel to
develop evidence-based recommendations informed by a systematic review of the literature.
Results
When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life
(QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and
radium-223 (223Ra; for men with predominantly bone metastases). Improved survival and QOL with
moderate toxicity risk are associated with docetaxel/prednisone. For asymptomatic/minimally symptomatic
men, improved survival with unclear QOL impact and low toxicity are associated with sipuleucel-T. For men
who previously received docetaxel, improved survival, unclear QOL impact, and moderate to high toxicity
risk are associated with cabazitaxel/prednisone. Modest QOL benefit (without survival benefit) and high
toxicity risk are associated with mitoxantrone/prednisone after docetaxel. No benefit and excess toxicity are
observed with bevacizumab, estramustine, and sunitinib.
Recommendations
Continue androgen deprivation (pharmaceutical or surgical) indefinitely. Abiraterone acetate/
prednisone, enzalutamide, or 223Ra should be offered; docetaxel/prednisone should also be
offered, accompanied by discussion of toxicity risk. Sipuleucel-T may be offered to asymp-
tomatic/minimally symptomatic men. For men who have experienced progression with
docetaxel, cabazitaxel may be offered, accompanied by discussion of toxicity risk. Mitoxan-
trone may be offered, accompanied by discussion of limited clinical benefit and toxicity risk.
Ketoconazole or antiandrogens (eg, bicalutamide, flutamide, nilutamide) may be offered,
accompanied by discussion of limited known clinical benefit. Bevacizumab, estramustine, and
sunitinib should not be offered. There is insufficient evidence to evaluate optimal sequences
or combinations of therapies. Palliative care should be offered to all patients.
J Clin Oncol 32:3436-3448. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Prostate cancer is the second leading cause of cancer
deaths among North American men, with an esti-
mated 29,720 deaths in 2013 in the United States1
and 3,900 deaths in Canada.2 For men with
androgen-sensitive metastatic disease, continuous
androgen-deprivation therapy is the current stan-
dard of care.3 Ultimately, many of these men will
develop castration-resistant prostate cancer (CRPC),
warranting additional lines of therapy added to
androgen-deprivation therapy.4 This guideline per-
tains to men with CRPC and radiographically or
pathologically demonstrated metastases.
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THE BOTTOM LINE
ASCO GUIDELINE UPDATE
Recommendations From American Society of Clinical Oncology and Cancer Care Ontario for Systemic
Therapy in Men With Metastatic Castration-Resistant Prostate Cancer, Based on Standardized Ratings of
Clinical Benefit, Harm, Evidence Strength, and Recommendation Strength*
Guideline Question
● Which systemic therapies improve outcomes in men with metastatic castration-resistant prostate cancer (CRPC)?
Target Audience and Population
● The target audience for this guideline comprises medical, radiation, and urologic oncologists who treat men with metastatic
CRPC. These recommendations are also intended to inform patients, caregivers, health care professionals, health care administra-
tors, and policymakers.
Methods
● Expert panel recommendations based on a systematic review of the medical literature updated to June 2014.
Recommendations
Androgen-Deprivation Therapy:
● Continuous androgen deprivation (pharmaceutical or surgical) should be continued indefinitely regardless of additional therapies.
(Benefit: moderate; harm: moderate; evidence strength: weak; recommendation strength: moderate)
Therapies in Addition to Androgen-Deprivation Therapy:
Therapies with demonstrated survival and quality-of-life benefits:
● Abiraterone acetate and prednisone should be offered.
(Benefit: moderate; harm: low; evidence strength: strong; recommendation strength: strong)
● Enzalutamide should be offered.
(Benefit: moderate; harm: low; evidence strength: strong; eecommendation strength: strong)
● Radium-223 should be offered to men with bone metastases.
(Benefit: moderate; harm: low; evidence quality: strong; recommendation strength: strong)
● Docetaxel and prednisone should be offered.†
(Benefit: moderate; harm: moderate; evidence strength: strong; recommendation strength: moderate)
Therapies with demonstrated survival benefit and unclear quality-of-life benefit:
● Sipuleucel-T may be offered to men who are asymptomatic or minimally symptomatic.
(Benefit: moderate; harm: low; evidence strength: moderate; recommendation strength: weak)
● Cabazitaxel and prednisone may be offered to men who experience progression with docetaxel
(Benefit: moderate; harm: moderate to high; evidence strength: strong; recommendation strength: moderate)
Therapies with quality-of-life benefit without demonstrated survival benefit:
● Mitoxantrone plus prednisone may be offered.
(Benefit: low; harm: high; evidence strength: weak; recommendation strength: weak)
Therapies with biologic activity and unknown survival or quality-of-life benefit:
● Antiandrogens (eg, bicalutamide, flutamide, nilutamide) may be offered.
(Benefit: low; harm: low; evidence strength: weak; recommendation strength: weak)
● Ketoconazole may be offered.
(Benefit: low; harm: moderate; evidence strength: weak; recommendation strength: weak)
● Low-dose corticosteroid monotherapy may be offered.
(Benefit: low; harm: low; evidence strength: weak; recommendation strength: weak)
(continued on following page)
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This guideline builds on prior recommendations from the Amer-
ican Society of Clinical Oncology (ASCO) and Cancer Care Ontario
(CCO). In 2006, the CCO Genitourinary Cancer Disease Site Group
developed a guideline on nonhormonal therapies for men with met-
astatic CRPC based on a systematic review of 28 randomized con-
trolled trials (RCTs) published between 1979 and 2004.5 In 2007,
ASCO endorsed the CCO guideline,6 which recommended docetaxel
with prednisone as the mainstay of treatment for patients with symp-
tomatic metastatic CRPC.7
In an update of the literature through June 2012,8 CCO expanded
the scope of the prior systematic review to include targeted therapies
and immunotherapy. That review included an additional 25 RCTs.5,8
On the basis of this evidence, ASCO and CCO convened an expert
panel to provide the current recommendations for systemic therapy in
metastatic CRPC. A description of standardized criteria used by ASCO
and CCO to make these recommendations is shown in the Method-
ology Supplement. These criteria include evaluations of the strength of
published evidence, clinical benefit, and risk of harm.
THE BOTTOM LINE (CONTINUED)
Therapies without demonstrated survival or quality-of-life benefit:‡
● Bevacizumab should not be offered.
(Benefit: none; harm: high; evidence strength: moderate; recommendation strength: strong)
● Estramustine should not be offered.
(Benefit: none; harm: high; evidence strength: moderate; recommendation strength: strong)
● Sunitinib should not be offered.
(Benefit: none; harm: high; evidence strength: moderate; recommendation strength: strong)
Palliative Care Services
● Palliative care should be offered to all patients, particularly to those exhibiting symptoms or quality-of-life (QOL) decrements,
regardless of treatment type.
(Benefit: moderate; harm: none; evidence strength: moderate; recommendation strength: strong)
Qualifying Statements
● Clinicians are advised to review the published regimens discussed in this guideline for their use in appropriate patient populations
and for applicable dose selections/modifications, available from the product labels.
● There is insufficient published evidence to recommend specific sequencing of these therapies or combinations of these therapies,
except as otherwise noted.
● The distinction made in some clinical trials between pre- and postdocetaxel treatment contexts should not play a role in selecting
therapies for individual patients, unless otherwise noted.
● Patients may place a higher importance on QOL rather than length of life. It is essential to understand individual patient values
and preferences for appropriate treatment decision making. Many patients with incurable metastatic disease misperceive the goals
of care to be curative. Clear communication about goals as well as potential benefits and harms of care should be prioritized.
● Cost and availability considerations may reasonably influence treatment decisions. There is wide variation in the financial burden
individual patients face for various therapies, and this potential barrier or hardship should be openly discussed with patients.
● Most phase III clinical trials have included patients with good baseline performance status. The choice of treatment for patients
with diminished performance status is not clearly informed by existing evidence in most cases.
Additional Resources
● More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with information
about evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at www.asco.org/
guidelines/mCRPC. Patient information is available at www.cancer.net.
*Criteria for ratings of clinical benefit, harm, strength of evidence, and strength of recommendations are shown in
Methodology Supplement.
†Recent data suggest a substantial survival benefit when adding a limited course of docetaxel to androgen-deprivation therapy in the
setting of newly diagnosed metastatic androgen-sensitive prostate cancer, primarily in men with a high burden of metastatic disease at
presentation (visceral disease and/or > four bone metastatic lesions). The additive benefits or toxicities associated with subsequently re-
treating such patients with docetaxel in the castration-resistant setting are not known.45
‡Drug products are listed that have obtained regulatory approval and market availability for other indications. Products with negative
phase III clinical trial evidence are not listed if they are not approved or available.
Basch et al
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Topics not specifically covered in this guideline include manage-
ment of patients with androgen-sensitive prostate cancer, manage-
ment of prostate cancer recurrence based solely on detection of serum
prostate-specific antigen (PSA) without radiographic or pathologic
evidence of metastases (ie, biochemical progression), and bone health
in CRPC.
GUIDELINE QUESTION




The ASCO Clinical Practice Guidelines Committee and CCO Program
in Evidence-Based Care convened an expert panel with multidisciplinary rep-
resentation in medical oncology, urologic oncology, radiation oncology, com-
munity oncology, patient advocacy, health services, implementation research,
and guideline methodology. Members of the expert panel are listed in Appen-
dix Table A1 (online only).
Guideline Development Process
The expert panel met on several occasions and corresponded frequently
through e-mail; work on the guideline was completed primarily through the
writing group, along with ASCO staff. The purpose of the panel meetings was
for members to contribute content, provide critical review, and finalize the
guideline recommendations, including an assessment of benefits and harms
associated with treatments based on consideration of the evidence. All mem-
bers of the expert panel participated in preparation of the draft guideline
document, which was then disseminated for external review and submitted to
Journal of Clinical Oncology (JCO) for peer review. All ASCO guidelines are
reviewed and approved by the ASCO Clinical Practice Guideline Committee
on behalf of the ASCO Board before publication. All CCO guidelines are
reviewed and approved by the CCO Report Approval Panel and a topic-
specific disease site group (in this instance, the CCO Genitourinary Disease
Site Group).
Guideline Disclaimer
ASCO Clinical Practice Guidelines and other guidance published herein
are provided by ASCO to assist providers in clinical decision making. The
information herein should not be relied on as being complete or accurate, nor
should it be considered as inclusive of all proper treatments or methods of care
or as a statement of the standard of care. With the rapid development of
scientific knowledge, new evidence may emerge between the time information
is developed and when it is published or read. The information is not contin-
ually updated and may not reflect the most recent evidence. The information
addresses only the topics specifically identified herein and is not applicable to
other interventions, diseases, or stages of disease. This information does not
mandate any particular course of medical care. Furthermore, the information
is not intended to substitute for the independent professional judgment of the
treating provider, because the information does not account for individual
variation among patients. Recommendations reflect high, moderate, or low
confidence that the recommendation reflects the net effect of a given course of
action. Use of words like must, must not, should, and should not indicates that
a course of action is recommended or not recommended for either most or
many patients, but there is latitude for the treating physician to select other
courses of action in individual cases. In all cases, the selected course of action
should be considered by the treating provider in the context of treating the
individual patient. Use of the information is voluntary. ASCO provides this
information on an as-is basis and makes no warranty, express or implied,
regarding the information. ASCO specifically disclaims any warranties of
merchantability or fitness for a particular use or purpose. ASCO assumes no
responsibility for any injury or damage to persons or property arising out of or
related to any use of this information or for any errors or omissions.
Guideline and Conflicts of Interest
The expert panel was assembled in accordance with the ASCO Conflict of
Interest Management Procedures for Clinical Practice Guidelines (summa-
rized at http://www.asco.org/rwc). Members of the panel completed the
ASCO disclosure form, which requires disclosure of financial and other inter-
ests that are relevant to the subject matter of the guideline, including relation-
ships with commercial entities that are reasonably likely to experience direct
regulatory or commercial impact as a result of promulgation of the guideline.
Categories for disclosure include employment relationships, consulting ar-
rangements, stock ownership, honoraria, research funding, and expert testi-
mony. In accordance with these procedures, the majority of the members of
the panel did not disclose any such relationships. The Methodology Supple-
ment provides full guideline disclaimers from CCO.
Literature Review
ASCO and CCO guidelines are based on systematic reviews of the liter-
ature. A protocol for each systematic review defines parameters for a targeted
literature search. Additional parameters include relevant study designs, litera-
ture sources, types of reports, and prespecified inclusion and exclusion criteria
for identified literature. This guideline protocol was reviewed and approved by
the ASCO Clinical Practice Guidelines Committee Methodology Subcommit-
tee and the CCO Program in Evidence-Based Care leadership.
Literature Search Strategy
For this clinical practice guideline, the literature search to June 2012 and
results of the systematic review conducted by CCO8 were considered to be of
high quality and currency to be endorsed for use by the guideline expert panel.
An updated search of the Medline database was conducted to June 2014 to
search for any additional RCTs that could inform recommendations. The
literature search will be replicated for periodic updates of the guideline. Addi-
tions to this guideline were triggered by publications and meeting presenta-
tions of phase III clinical trials through June 2014.
Study Selection Criteria
Articles were selected for inclusion in the CCO systematic review if they:
● Were RCTs or evidence synthesis products based on RCTs
● Included men with metastatic CRPC
● Compared systemic therapy, alone or in combination with other
agents, versus placebo or other drug regimens
● Were published English-language reports
Articles were excluded from the systematic review if they involved only
androgen-deprivation therapy, bone targeted agents, or radionuclides. Trials
were required to have  50 patients per study arm, and in mixed study
populations,  90% of men were required to have metastases.
RESULTS
On the basis of a 2012 CCO systematic review8 and an updated search
of the Medline database to June 2014, a total of 26 RCTs9-37 informed
this clinical practice guideline (Table 1). Publication of the phase III
ALSYMPCA (Alpharadin in Symptomatic Prostate Cancer) trial,31
evaluating radium-223 (223Ra) and US Food and Drug Administra-
tion approval of this product in May 2013, and publication of the
phase III PREVAIL trial,38 evaluating enzalutamide in the prechemo-
therapy setting, prompted inclusion of these data for this guideline.
Although only the most recent reports from multiple publications are
referenced throughout, supporting evidence is also cited where appro-
priate. A search for clinical practice guidelines developed in 2013
yielded two clinical practice guidelines, one by the National Compre-
hensive Cancer Network (NCCN)39 and the other by the American
Urological Association (AUA).40
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Study Quality Assessment and Limitations
of Literature
In the CCO review,8 study quality was formally assessed and
summarized by one reviewer for the RCTs identified. In that review,
design aspects related to individual study quality were generally as-
sessed as moderate to high quality, with factors such as blinding,
allocation concealment, placebo control, intention to treat, and fund-
ing sources, generally indicating a relatively low risk of bias for most of
the identified trials (Table 2). Since the time of that quality appraisal,
two of the trials have published their findings, with additional details
reported around quality elements. Hence, the quality appraisal from
the CCO review is slightly more conservative in its estimation of
potential biases associated with the body of evidence.
Several factors related to increased potential for bias for the over-
all body of evidence to inform recommendations were also reported.
Seven of the trials were phase II studies, seven trials were terminated
early, three trials offered crossover after preplanned interim analyses,
and four trials were reported as conference proceedings (Table 1).
Primary outcomes varied across the trials, and in the majority of cases,
studies were not directly comparable, because different treatments
and regimens were used at different time points in the patient treat-
ment trajectory.
One included phase III double-blind RCT31 was published sub-
sequent to the CCO quality appraisal.8 In that trial, 921 patients were
randomly assigned at a ratio of two to one to 223Ra or placebo. That
trial was terminated for efficacy as part of a preplanned interim anal-
ysis. Using the same quality metrics reported in the CCO review, that
trial was not considered to be at high risk of potential bias.
Clinical Practice Guidelines
Two clinical practice guidelines were identified, one by the
NCCN39 and one by the AUA.40 A summary of these recommenda-
tions is presented in the Data Supplement. Although the recommen-
dations from the NCCN, AUA, and ASCO/CCO guidelines are
similar, the ways in which therapies are categorized differ. The NCCN
guideline39 separates patients by nonmetastatic versus metastatic and
nonsymptomatic versus symptomatic status and further separates
symptomatic patients by first- or second-line treatment. The AUA
guideline40 separates patient populations by nonmetastatic versus
metastatic status and further divides the metastatic patients by prior
docetaxel versus no prior docetaxel, asymptomatic versus symptom-
atic status, and good versus poor performance status. In contrast, this
guideline categorizes and evaluates therapies based on type of clinical
benefit (survival and/or quality of life [QOL]), strength of evidence,
and benefit-risk balance. Pertinence of particular therapies to presence
of symptoms, bone metastases, or prior treatments is noted at the
individual therapy level.
Trial Results
As listed in Table 1, six trials investigated systemic therapy
agents delivered before chemotherapy-containing regimens.9,10,12-15
Thirteen RCTs compared docetaxel-containing systemic therapy
as control versus other cytotoxic chemotherapy, targeted ther-
apy, or immunotherapy, with or without docetaxel, as the
intervention.11-13,18,19,22-25,29,32-35 One RCT compared 223Ra with
placebo among patients with or without prior chemotherapy
exposure,31 and five trials investigated systemic therapy agents
administered to patients who had previously received docetaxel-
containing chemotherapy.15,36,39,41-43 Details of the evidence are
described here, organized alphabetically by individual drug prod-
uct name.
Abiraterone acetate. In a phase III trial of abiraterone acetate
plus prednisone administered in men with metastatic CRPC who had
not received chemotherapy and were asymptomatic or beginning to
exhibit symptoms, a statistically significant progression-free survival
(PFS) difference was detected when compared with placebo plus pred-
nisone (hazard ratio [HR], 0.43; 95% CI, 0.35 to 0.52; P  .001).15
Secondary outcomes, including time to opiate use, time to pain pro-
gression, chemotherapy initiation, functional status deterioration,
and PSA progression, demonstrated significant benefit in favor of
abiraterone acetate (all P  .01). Median overall survival (OS) in the
control group was 27.2 months, whereas median survival in the inter-
vention group was not reached by the time of analysis (HR, 0.75; 95%
CI, 0.61 to 0.93; P  .0097). The prespecified  level for OS was P 
.0008; hence, there was a trend, but statistical significance was techni-
cally not reached for that outcome. QOL was measured through
patient report of pain using the Brief Pain Inventory–Short Form, and
functional status was assessed using the Functional Assessment of
Cancer Therapy–Prostate. Delay in pain was longer with abiraterone
acetate, at 26.7 versus 18.4 months (HR, 0.82; 95% CI, 0.67 to 1.00;
P  .049), as was the delay in functional decline, at 12.7 versus 8.3
months (HR, 0.78; 95% CI, 0.66 to 0.92; P  .003). The toxicity profile
associated with abiraterone acetate included a low rate of grade 3 to 4
adverse events, with no statistically significant differences between
treatment groups reported.
In another phase III trial of abiraterone acetate plus prednisone in
men who previously received docetaxel,36,37 significant differences in
median OS (15.8 v 11.2 months; HR, 0.74; 95% CI, 0.64 to 0.86; P 
.001), median time to PSA progression (8.5 v 6.6 months; HR, 0.63;
95% CI, 0.58 to 0.78; P  .001), median radiographic PFS (5.6 v 3.6
months; HR, 0.66; 95% CI, 0.58 to 0.76; P  .001), and PSA response
(29.5% v 5.5%; P  .001) were detected in favor of abiraterone acetate
when compared with prednisone plus placebo. Median time to func-
tional decline was longer with abiraterone acetate, at 5 versus 3 months
(P  .001),43 as were significant improvements in patient-reported
fatigue, compared with prednisone alone.44
Table 2. Summary of CCO Quality Assessment of Included RCTs
Criterion Yes No Not Reported
Was allocation sequence reported? 16 0 9
Was concealed allocation reported? 6 0 19
Was sample size/power calculation reported? 16 4 5
Was blinding reported? 16 6 3
Was intention to treat reported? 13 9 3
Was patient withdrawal described? 14 0 11
Was industry funding reported? 15 1 9
Was loss to follow-up reported? 13 0 12
Were baseline characteristics balanced? 17 3 5
Was trial terminated early? 7 18 0
NOTE. In assessment of quality, “yes” indicates that quality metric was
met and/or was specifically reported, whereas “no” indicates that quality
metric was not met. “Not reported” indicates that quality metric may or
may not have been met; however, because it was not reported, it was not
possible to assess.
Abbreviations: CCO, Cancer Care Ontario; RCT, randomized controlled trial.
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Cabazitaxel. For patients who experienced progression during
or shortly after docetaxel treatment, a phase III trial comparing caba-
zitaxel plus prednisone versus mitoxantrone plus prednisone reported
a significant OS benefit of 15.1 versus 12.7 months (P  .001) and
median PFS of 2.8 versus 1.4 months with cabazitaxel (HR, 0.74; 95%
CI, 0.64 to 0.86; P  .001).32,41 QOL benefit was not clearly demon-
strated (small nonsignificant improvement in pain compared with
mitoxantrone was seen, although rates of pain palliation in both arms
were low; overall or prostate-specific QOL was not assessed).38 Grade
3 to 4 adverse events, most commonly neutropenia (82% v 58%; P not
reported), febrile neutropenia (8% v 1%; P not reported), and diar-
rhea (6% v 1%; P not reported), were greater in the cabazitaxel arm.
Docetaxel-containing regimens. A phase III trial of docetaxel plus
prednisone administered every 3 weeks reported a significant OS
advantage when compared with mitoxantrone plus prednisone (19.2 v
16.3 months; HR, 0.79; 95% CI, 0.67 to 0.93; P  .004) and no
significant difference in survival compared with a second intervention
arm of docetaxel once per week.18 There were significantly more grade
3 to 4 adverse events with docetaxel administered every 3 weeks when
compared with mitoxantrone as well as with once-per-week do-
cetaxel. In the once-per-week docetaxel arm, clinical benefit was gen-
erally greater than that seen with mitoxantrone but lower than that
with docetaxel every 3 weeks, although these differences were not
statistically significant. Using the Functional Assessment of Cancer
Therapy–Prostate, functional status was significantly better with do-
cetaxel administered every 3 weeks (22%) or once per week (23%)
when compared with mitoxantrone (13%; P  .009 and .005, respec-
tively). One docetaxel timing trial reported a longer time to treatment
failure (5.6 v 4.9 months; P  .016) and fewer grade 3 to 4 toxicities
overall with docetaxel administered every 2 versus every 3 weeks.17
Regarding the use of estramustine with docetaxel, in the original
CCO guideline, one phase III trial reported that the combination of
docetaxel and estramustine produced superior OS results when com-
pared with mitoxantrone plus prednisone, but that regimen was not
recommended on the basis of increased adverse events.5 In a subse-
quent phase II trial, the combination of docetaxel plus estramustine
was not superior to docetaxel alone, and adverse events were greater in
the estramustine arm.20
In five trials of docetaxel-containing chemotherapy with or with-
out targeted therapy for patients with symptomatic metastatic CRPC,
one trial reported that the addition of bevacizumab to docetaxel plus
prednisone resulted in improved PFS (9.9 v 7.5 months; P  .001),
PSA response, and objective response but not OS when compared
with docetaxel and prednisone alone. There were significantly more
grade 3 to 4 adverse effects (75% v 56%; P  .001), including
treatment-related death (4.0% v 1.2%; P  .005), when compared
with the docetaxel control.21 No significant differences in clinically
meaningful outcomes were detected in the remaining four RCTs.22-25
Recent data suggest a substantial survival benefit when adding a
limited course of docetaxel to androgen-deprivation therapy in the
setting of newly diagnosed metastatic androgen-sensitive prostate
cancer. The additive benefits or toxicities associated with subsequently
re-treating such patients with docetaxel in the castration-resistant
setting are not known.45
Enzalutamide. In a phase III trial of 1,199 men with prior chem-
otherapy exposure who were randomly assigned to receive enzalut-
amide versus placebo, a statistically significant improvement in OS of
18.4 versus 13.6 months was detected with enzalutamide (HR, 0.63;
95% CI, 0.53 to 0.75; P  .001).28,35 Radiographic PFS was 8.3 versus
2.9 months (HR, 0.40; P  .001), PSA response was 54% versus 2%
(P  .001), time to PSA progression was 8.3 versus 3.0 months (HR,
0.25; P  .001), and time to first skeletal-related event was 16.7 versus
13.3 months (HR, 0.69; P  .001), all in favor of enzalutimide. Overall
QOL benefit was observed in 43% versus 18% (P  .001) of patients
receiving enzalutamide compared with placebo, whereas fatigue, diar-
rhea, and hot flushes were more common with enzalutamide. Five
patients (0.6%) experienced seizures in the enzalutamide group.35
In one phase III trial, 1,717 men without prior chemotherapy
exposure were randomly assigned to receive enzalutamide versus pla-
cebo.38 At data cutoff, 72% of men were alive in the enzalutamide arm
compared with 63% in the placebo arm (risk reduction, 29%; HR,
0.71; P  .001). Significant improvements in PFS, PSA, skeletal-
related events, and QOL were also associated with enzalutamide over
placebo. No new safety signals were detected (one seizure in
each arm).
Mitoxantrone. A prior CCO systematic review reported on three
small trials of mitoxantrone plus prednisone or hydrocortisone, which
showed modest clinical benefit (including improved pain response,
QOL, and/or time to disease progression) but no improvement in OS,
and increased risk of harm, compared with treatment with prednisone
or hydrocortisone alone.5 In a trial comparing mitoxantrone plus
prednisone with prednisone alone during the era before availability of
most contemporary prostate cancer therapies, there was a 29% pain
response rate for mitoxantrone versus 12% for prednisone alone,46
although in a more contemporary phase III trial comparing cabazi-
taxel with mitoxantrone in men who had previously received do-
cetaxel, mitoxantrone plus prednisone was associated with a 7.7%
pain response rate.18
223Ra. The ALSYMPCA phase III trial reported median and OS
benefits with 223Ra compared with placebo in an interim analysis,
which resulted in early trial stoppage because of efficacy (median
survival, 14.9 v 11.3 months; HR, 0.70; 95% CI, 0.58 to 0.83; P 
.001).31 Enrollment criteria for this trial included men with  two
metastases to bone and excluded men with visceral metastases or
lymphadenopathy  3 cm in the short axis diameter. A majority of
enrollees were using opiate analgesics at the time of enrollment. Mod-
est QOL benefit was seen in favor of 223Ra, with 25% of patients
experiencing meaningful improvements in QOL, compared with 16%
in the placebo arm (P  .02). A dedicated pain assessment was not
included in the trial. A subgroup analysis found lack of significant
benefit in men with  six metastases.
Sipuleucel-T. The IMPACT (Immunotherapy Prostate Adeno-
carcinoma Treatment) phase III trial reported a statistically significant
4.1-month median OS advantage with sipuleucel-T versus placebo
(HR, 0.78; 95% CI, 0.61 to 0.98; P  .03).14 No significant differences
were reported between treatment groups with regard to PSA response
or objective disease progression. QOL was not reported. No statisti-
cally significant differences in grade 3 to 5 adverse events were re-
ported (sipuleucel-T, 31.7% v placebo, 35.1%; P not reported). These
efficacy results are consistent with a combined analysis of two smaller
randomized trials reported previously.47
Therapies without definitive phase III data. Evidence for these
therapies (ketoconazole, antiandrogens [eg, bicalutamide, flutamide,
nilutamide], low-dose corticosteroid monotherapy) was previously
evaluated as part of a separate ASCO systematic review of second-line
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hormonal therapies in CRPC. OS and QOL outcomes are not estab-
lished, but there is evidence of activity for each and established mech-
anisms of action. In one phase III trial, the addition of ketoconazole to
antiandrogen withdrawal produced greater PSA and objective re-
sponses than antiandrogen withdrawal alone, but no differences in
OS, and 21% of patients experienced grade 3 or 4 adverse events.48 It is
notable that this study was not powered to detect an OS end point, and
crossover was allowed on progression. In a retrospective review of 138
patients started on low-dose ketoconazole (200 mg three times per
day), 28% of patients had a PSA response.49 Fifty-five patients (40%)
subsequently received high-dose ketoconazole (400 mg three times
per day); 13% of patients had an additional PSA response (P not
reported). In general, high-dose ketoconazole was associated with a
greater risk of adverse effects, and 11% of patients discontinued ther-
apy because of adverse effects resulting from high-dose therapy. For
patients who could not tolerate high-dose ketoconazole therapy, low-
dose ketoconazole had similar efficacy.
In trials of bicalutamide versus diethylstilbestrol,50 prednisone
versus flutamide,51 high- versus low-dose megestrol acetate,52 and
dexamethasone versus megestrol acetate,53 there were no meaningful
objective differences in outcome detected between treatment groups.
In the prednisone-alone (10 mg per day) control arm of phase III
clinical trial, PSA response was seen in 25% of patients,15 and a 28.8%
pain response was seen with prednisone alone in the control arm of a
different trial,54 although no placebo comparisons were included.
Negative trials and non–phase III trials. Clinical trials of several
products have been conducted without evidence of overall benefit in
clinically meaningful patient outcomes, including atrasentan,13,22 be-
vacizumab,21 calcitrol,28,29 GVAX,26,27 orteronel,55,56 satraplatin,24
sunitinib,34 and zibotentan.30 Products have been tested alone or in
addition to docetaxel. Of these, bevacizumab and sunitinib have been
approved by regulatory authorities for other indications. The panel
notes that although PFS did improve with some of these therapies, PFS
is not an accepted surrogate end point in CRPC, and in the absence of
demonstrated benefit in how patients feel, function, or survive, such
improvement cannot be considered clinically meaningful. The panel
also notes that results of a phase III trial of ipilimumab (after do-
cetaxel) have been publicly reported, but not yet published, without
demonstrated significant clinical benefit. Phase III results of a trial of
tasquinimod and ipilumimab predocetaxel are not yet available.57
Clinical Interpretation
In the context of incurable metastatic cancer, it is the opinion of
the panel that the goal of treatment is to provide the best possible QOL
for as long as possible. Over the past decade, multiple therapies have
become available for metastatic CRPC that provide OS benefit (al-
though generally modest and measured in months), as well as QOL
and pain benefits, demonstrated through well-designed phase III tri-
als. Before that time, options were more limited, with unfavorable
benefit-risk balance and limited quality evidence for most available
therapies. In the contemporary selection of treatments, attention
should be given to clinically meaningful benefit, risk of harm, quality
of evidence, and cost when assisting patients with treatment decisions.
Some patients may reasonably opt against treatment because of
toxicity or cost.58 Many of the therapies discussed in this guideline
have high costs associated with them when compared historically with
prior oncology drug products (Table 3), and out-of-pocket costs for
patients can be considerable, leading to potential financial hardship.
Cost-effectiveness assessment is not included in this guideline, but
several of the discussed therapies have been found not to be cost
effective by various authorities worldwide because of high cost relative
to overall benefit.
Moreover, evidence demonstrates that many patients with incur-
able metastatic cancers believe that the goal of treatment is cure rather
than palliation.62 Therefore, it is essential when discussing treatment
options to determine the values and preferences of patients, commu-
nicate the goals of care, and clearly describe the benefits, harms, and
financial impact of therapy options to the best of one’s ability.
When added to androgen deprivation, there are three treatments
for which there is strong evidence of survival as well as QOL benefit,
with a favorable benefit-risk profile: abiraterone acetate, enzalut-
amide, and 223Ra (for patients with predominantly bone metastases).
Abiraterone acetate has been evaluated in men both before and after
docetaxel chemotherapy. In a predocetaxel trial, multiple clinical end
Table 3. Treatment Costs in Patients With CRPC for 30-Day Period








Abiraterone acetate 2011 5,171.90 6,409.11
Bicalutamide 1995 Generic, 82; brand, 520 Generic, 28;
brand, 527
Cabazitaxel† 2010 11,233.78 12,806.06
Degarelix 2008 445.53 536.75




Enzalutamide 2012 ‡ 7,906.34
Flutamide 1989 79.65 125.80
Goserelin acetate 1995 596.00 210.32
Ketoconazole 1999 66.52 19.22
Leuprolide acetate 1998 356.00 202.84
Mitoxantrone† 1987 615.63 203.96
Nilutamide 1996 464.13 4,201.38
Prednisone 1974 3.75 6.50
Radium-223 2013 12,455.00‡ 12,455.00‡
Sipuleucel-T§ 2010 40,670.42 34,672.58
Abbreviations: CRPC, castration-resistant metastatic prostate cancer;
MSKCC, Memorial Sloan Kettering Cancer Center.
Large group commercial rates were calculated using health care claims from
Truven Health Analytics MarketScan Commercial Claims and Encounters
database.59 Calculation is based on total reimbursement for services rendered
based on most common supply of each product (30 days for most oral
medications or per infusion for injectable medications).
†Indicates regimen of every 3 weeks (sipuleucel-T and radium-223 are
limited-course therapies). Prices represent median dollars paid by both pa-
tients and insurers between 2010 and 2011 for each product use. Medicare
rates were calculated using methodology developed at Center for Health
Policy and Outcomes at MSKCC,60 described by Bach et al.61 For each oral
medication, 2013 full drug price was identified using the Medicare Plan Finder
tool. For each infused medication, dosage for original US Food and Drug
Administration–approved indication was used, and reimbursement rate was
taken from fourth-quarter 2013 average sales price files. Medicare rates are
standardized to monthly price. Price discrepancies between commercial
insurance and Medicare may represent differences in price between periods
(commercial, 2010 to 2011; Medicare, 2013) or impact of generic entry on
price (eg, docetaxel). For infused medications, differences between per-use
and monthly price estimates may be evident, particularly for drugs adminis-
tered less frequently than every month (eg, goserelin acetate). Some products
are administered for limited set time periods (eg, sipuleucel-T, radium-223),
and prices represent fraction of total course cost during abbreviated period.
‡Product not used during period when data were available. Prices for
radium-223 were obtained from MSKCC Web site, which were estimated
from media reports at time of last update.
§Same as † footnote, but indicates regimen of every 2 weeks.
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points were favorable, including pain and QOL, with a strong trend in
favor of OS. In the postdocetaxel trial, statistically significant benefits
in OS, pain, and QOL were seen. Enzalutamide has been evaluated
favorably after docetaxel, with recently reported favorable results of a
phase III trial in men before receiving docetaxel.38 Notably, patients in
published phase III trials of abiraterone acetate and enzalutamide had
not previously received the other agent, leaving open questions re-
garding sequencing or combinations of treatments, which are being
evaluated in ongoing and planned trials. 223Ra was favorably evaluated
in men who either received or did not receive prior docetaxel (phase
III trial included patients who received, were not eligible to receive, or
declined docetaxel, yielding 43% of participants who had not received
prior docetaxel). OS was significantly improved, and although pain
response was not explicitly evaluated as an end point, QOL measure-
ment demonstrated overall benefit. A majority of men were receiving
analgesics at baseline, suggesting that men with pain related to bone
metastases are most likely to benefit from the palliative properties of
223Ra, although men without pain may also experience QOL benefit or
delay in development of pain. Men with visceral metastases or lymph-
adenopathy  3 cm were excluded, and a subgroup analysis found
significant benefits restricted to men with  six bone metastases,
suggesting benefit is likely greatest among men for whom bone me-
tastases, and not soft tissue disease, are the principal concern. The
toxicity profile of 223Ra is favorable when historically compared with
other radiopharmaceuticals used in this population. It is not known
whether combining 223Ra with other treatments improves clinical
outcomes. 223Ra should be considered for patients with bone disease,
whereas abiraterone or enzalutamide should be considered for those
with bone and/or soft tissue disease. Use of any of these agents in
combination should be restricted to the context of prospective clini-
cal trials.
The distinction between pre- and postdocetaxel treatment con-
texts has been included in some clinical trials and regulatory review
assessments, but the panel concludes that this distinction is of limited
clinical usefulness when selecting treatment for an individual patient.
Therefore, evidence of efficacy for agents was considered, regardless of
relationship to prior chemotherapy, and the therapies discussed here
are all considered to be reasonable choices for men who have or have
not received docetaxel.
Docetaxel with prednisone remains an acceptable therapy to
offer patients based on strong evidence of improved survival, pain,
and overall QOL, but it has a relatively higher risk of toxicity when
compared historically with abiraterone, enzalutamide, or 223Ra. Po-
tential harms of this therapy should be discussed with patients at the
time of decision making in relation to the apparently lower risk of
harms associated with other options and to the patient’s individual
circumstances. If administered, docetaxel should be given every 3
weeks, which has been shown to be superior to a once-per-week
schedule. Results of a phase III trial among men with newly diag-
nosed metastatic androgen-sensitive prostate cancer suggest a sub-
stantial survival benefit when adding docetaxel chemotherapy to
androgen-deprivation therapy.45,63 At the time of this guideline
update, these results are available only as a meeting presentation
and not yet published.
Sipuleucel-T has been reported to significantly improve OS
among men who are asymptomatic or mildly symptomatic (ie,
have mild pain related to prostate cancer). Impact on QOL was not
formally studied. Risks of harm are relatively low. Although con-
troversies have been raised in editorials regarding the conduct of
clinical research of this product, based on the trial results, it re-
mains an option that may reasonably be discussed with patients
who have a low symptom burden.
Cabazitaxel with prednisone, when administered to men who
have received prior docetaxel, offers a statistically significant OS ben-
efit, although it does not seem to substantially improve pain; impact
on QOL is not known, but it carries a substantial toxicity profile.
Although pain results seemed similar to those in the mitoxantrone
control arm of the phase III trial, those response rates were substan-
tially lower than in the initial phase III mitoxantrone trial. Cabazitaxel
with prednisone may be offered to men who have received prior
therapies involving a more favorable benefit-risk profile, accompa-
nied by a discussion of the risk of harms.
Mitoxantrone offers no demonstrated survival benefit. Although
initial research in the 1990s reported a pain response rate of 29%, more
recent evaluation in a more heavily pretreated population found only
a 7.7% pain response rate. Given the high risk of toxicity, mitoxan-
trone may be less attractive to patients. This therapy may be commer-
cially available where others are not and is generally less costly. If
offered to patients, it should be accompanied by a discussion of the
clinical benefits and risk of harms.
There are limited data regarding the clinical benefits of older
antiandrogens (eg, bicalutamide, flutamide, nilutamide), ketocona-
zole, and prednisone. Antiandrogens carry relatively few toxicities and
vary in cost. Ketoconazole carries higher adverse effects and is rela-
tively inexpensive. These products are less efficacious than more re-
cently developed drugs with similar mechanisms, but they may be
more accessible for some patients and in low-resource contexts.
These drugs may be considered particularly for patients with lower
disease burden or limited other options, accompanied by a discussion
of the unclear clinical benefits and potential toxicities.
Prednisone monotherapy at a low dose (eg, 10 mg per day) seems
to have activity in CRPC, may be particularly beneficial for pain
palliation (eg, as seen in control arms of abiraterone acetate controlled
trials), and is inexpensive, although its effects on survival are
not known.
RECOMMENDATIONS
These recommendations were developed based on systematic re-
views of the scientific literature and expert panel consensus, based
on the best available evidence and clinical experience as a guide.
They are evidence based and informed by RCT data. Summary
descriptions of results are provided in the literature review and
analysis section and are presented fully in the systematic review of
the literature.7 Ratings for the type of recommendation and
strength of the evidence are offered (Methodology Supplement
provides rating definitions).
These guideline recommendations were crafted, in part, using
the Guidelines Into Decision Support (GLIDES) methodology and
accompanying BRIDGE-Wiz software64 (Methodology Supplement).
A guideline implementability review was conducted to improve clarity
around recommended actions for clinical practice. Details of the im-
plementation review are provided in the Appendix (online only).
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PATIENT AND CLINICIAN COMMUNICATION
Patients should be fully informed about the extent of potential benefit
as well as harm and cost of treatment before making decisions. ASCO
and CCO consider it essential to good clinical practice to assure that
this information and the goals of care are understood.
Many patients misunderstand the goals of care in the setting of
metastatic disease to be curative rather than palliative. This may lead to
decisions to accept excess toxicity or cost based on incorrect assump-
tions about potential benefit. Palliative care should be offered to all
patients, particularly to those exhibiting symptoms or QOL decre-
ments, and is recommended in a separate ASCO document.65
HEALTH DISPARITIES
Although ASCO clinical practice guidelines represent expert recom-
mendations on the best practices in disease management to provide
the highest level of cancer care, it is important to note that many
patients have limited access to medical care. Economic and racial/
ethnic disparities in health care contribute significantly to this prob-
lem. Patients with cancer in these populations have been shown in
many cases to suffer disproportionately from comorbidities, experi-
ence more substantial obstacles to receiving care, to be more likely to
be uninsured, and to be at greater risk of receiving lower quality care.
Many patients lack access to care because of geographic distance from
treatment facilities. Awareness of these disparities in access to care
should be considered in the context of this clinical practice guideline,
and health care providers should make extra efforts to deliver the
highest level of cancer care possible to these vulnerable populations.
Moreover, efforts are encouraged to enroll patient populations onto
clinical trials that are representative of the diversity of treated patients
in the community.
MULTIPLE CHRONIC CONDITIONS
Creating evidence-based recommendations to inform treatment of
patients with additional chronic conditions, a situation in which
the patient may have  two such conditions—referred to as mul-
tiple chronic conditions (MCCs)—is challenging. Patients with
MCCs are a complex and heterogeneous population, making it
difficult to account for all of the possible permutations to develop
specific recommendations for care. In addition, the best available
evidence for treating index conditions, such as cancer, is often from
clinical trials, the study selection criteria of which may exclude
these patients to avoid potential interaction effects or confounding
of results associated with MCCs. As a result, the reliability of
outcome data from these studies may be limited, thereby creating
constraints for expert groups to make recommendations for care in
this heterogeneous patient population.
Because many patients for whom guideline recommendations
apply present with MCCs, any treatment plan needs to take into
account the complexity and uncertainty created by the presence of
MCCs and highlight the importance of shared decision making re-
garding guideline use and implementation. Therefore, in consider-
ation of recommended care for the target index condition, the
clinician should review all other chronic conditions present in the
patient and take those conditions into account when formulating
treatment and follow-up plans.
In light of these considerations, practice guidelines should pro-
vide information on how to apply the recommendations for patients
with MCCs, perhaps as a qualifying statement for recommended care.
This may mean that some or all of the recommended care options are
modified or not applied, as determined by best practice in consider-
ation of any MCC.
For men with prostate cancer age  65 years, the 10 most com-
mon comorbid conditions are hypertension, hyperlipidemia, diabe-
tes, ischemic heart disease, anemia, arthritis, chronic kidney disease,
depression, chronic obstructive pulmonary disease, and heart failure.
For men with prostate cancer age  65 years, the 10 most common
comorbidities are hypertension, hyperlipidemia, ischemic heart dis-
ease, anemia, diabetes, arthritis, chronic kidney disease, cataract, heart
failure, and chronic obstructive pulmonary disease. Presence of any of
these comorbid conditions should be taken into account when decid-
ing on an individual treatment plan. Please refer to the table in the
Data Supplement for details on the number of patients affected by
these comordid conditions and other supplementary information.
COST IMPLICATIONS
As discussed previously and detailed in Table 3, some of the treatments
available in this setting are associated with considerable cost, and some
patients may decide against some treatments because of this.58 Al-
though a cost-effectiveness assessment is not included in this guide-
line, several of the discussed therapies have been found not to be cost
effective by various authorities worldwide because of high cost relative
to overall benefit.
EXTERNAL REVIEW
A draft of the clinical practice guideline was reviewed by 14 practitio-
ner content experts from the United States (n  8) and Canada (n 
6). Reviewers were asked in a structured questionnaire to rate the
quality of the guideline and whether they would make use of the
guideline and recommend it to others. They were asked for their
assessment of the barriers or enablers to implementation. This guide-
line was rated as high quality, and overall, practitioners agreed that the
guideline would be of use in their own professional decisions, as well as
in general clinical practice.
Identified barriers included recommending agents not available
in Canada, cost and funding of agents, controversy around the use of
sipuleucil-T as a standard option, and timing of initiation of addi-
tional therapies. To address this feedback, the recommendations were
restructured to allow for greater consideration of health setting and
drug availability and broader context on the use of sipuleucil-T, with
references provided. Detailed results of the external review are avail-
able on the CCO Web site at https://www.cancercare.on.ca/toolbox/
qualityguidelines/diseasesite/genito-ebs/.
GUIDELINE IMPLEMENTATION
ASCO guidelines are developed for implementation across health
settings. Barriers to implementation include the need to increase
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awareness of the guideline recommendations among front-line prac-
titioners and survivors of cancer and caregivers, as well as the need to
provide adequate services in the face of limited resources. The guide-
line Bottom Line Box was designed to facilitate implementation of
recommendations. This guideline will be distributed widely through-
out the ASCO Practice Guideline Implementation Network (Appen-
dix Table A2, online only). ASCO guidelines are posted on the ASCO
Web site and most often published in JCO and Journal of Oncol-
ogy Practice.
LIMITATIONS OF RESEARCH AND FUTURE DIRECTIONS
There is limited available evidence in the following areas of needed
research in metastatic CRPC:
● Optimum sequencing and combination of available therapies
● Efficacy of drugs in treatment sequences other than those
tested in clinical trials
● Potential benefits and harms of combining therapies
● Comparative QOL and symptomatic benefits of the-
rapy options
● Effectiveness of therapies in real-world populations
● Cost-benefit analysis in the US context
● Out-of-pocket costs faced by most patients
● Shared decision-making tools
● Clinical benefits of lower-cost therapies in low-
resource contexts
● Impact of early access to palliative care
● Alternative approaches to continuous androgen deprivation
The panel recommends inclusion of rigorously designed symptom
and QOL outcome measures in all phase III clinical trials in metastatic
CRPC. ASCO believes that cancer clinical trials are vital to inform
medical decisions and improve cancer care and that all patients should
have the opportunity to participate.
ADDITIONAL RESOURCES
Data Supplements, including evidence tables, and clinical tools and
resources can be found at www.asco.org/guidelines/mCRPC. Patient
information is available there and at www.cancer.net.
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1. Please indicate your contact information.
2. Is it clear for which patients and at what time one would use these recommendations?




(5) Very unclear ()
Comment: The choice of agents and their prioritization (“should offer,” “may offer”) are clearly defined in the prechemotherapy
setting, upon initiation of chemotherapy, and in the postchemotherapy setting. The manuscript discusses sufficiently the lack of data on
agent sequencing (ie, postdocetaxel setting) while providing a useful contextual discussion on this issue in the section on Clinical
Interpretation of Evidence.
3. Is it clear what action(s) the practitioner(s) should take (or not take), based on the recommendation(s)?




(5) Very unclear ()
Comment: The recommendations provided in the Bottom Line are focused and well written, as are the clarifying statements, as to
what the guideline does not cover or recommend and the lack of data to guide agent sequencing. The section on Clinical Considerations
compliments the recommendations.
4. Does the recommendation(s) have enough detail for people with various professional backgrounds (eg, physician extenders, pharma-
cists) who might implement the recommendation(s)?
(1) Too much detail ()
(2) ()
(3) Sufficient detail (X)
(4) ()
(5) Insufficient detail ()
Comment: Under the supervision of a treating oncologist, there are sufficient guideline details and patient population
caveats to permit the guidance of physician extenders and pharmacists involved in the implementation of these guidelines.
The manuscript also directs clinicians to review the papers from which these guidelines are derived for additional information
relevant to clinical care considerations.






Comment: The chances are high for consistency in the interpretation and execution of recommendations in the context of
“treatment settings” as defined in the manuscript. However, within the pre- and postchemotherapy settings (the latter, in particular) there
may be variability in agent selection based on physician preference. There is sufficient flexibility in the guidelines to permit agent selection
that may be offered based on patient characteristics and shared decision making.
6. Are actions implementable under current conditions (eg, FDA [US Food and Administration] approval, drug availability)? (Recom-
mendation may be either “aspirational” or implementable, but it is suggested that panels be explicit.)
(1) Very (X)
(2) ()
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(3) Neutral ()
(4) ()
(5) Not at all ()
Comment: The agents that “should” or “may” be recommended in the Bottom Line are currently FDA approved for this patient
population. Please see additional comments in Question 11.






Comment: The recommendations outlined in the Bottom Line are evidence based, and the discussion of these agents, as well as those
that are not recommended, is well critiqued in the manuscript. I believe the reviewed agents/trials and methodologies described in the
manuscript are sufficiently rigorous and balanced as to preclude being considered novel or unconventional approaches to guideline
derivation. The pilot effort using GLIDES [Guidelines Into Decision Support] and BRIDGE-Wiz is helpful in providing clarifying
language for guideline implementation.
8. Are the recommendation(s) sufficiently flexible to allow different providers to implement it/them?





Comment: They are sufficiently flexible. Also see my comments in Question 5.




Comment: My comment in this section relates to sipuleucel-T. For the use of sipuleucel-T, the practice would need to be familiar
with the unique logistical aspects in having this product available for their patients but I do not see this as a barrier to implementation in
a modern oncology practice. An oncology practice can implement the recommendations in this guideline.
10. Is the guideline similarly applicable to different types of practices including solo and small groups, large independent groups, and
hospital-based providers? If you answered “not at all applicable,” please identify specific barriers for specific practice setting(s).




(5) Not at all applicable ()
11. Are there currently payer restrictions of any kind that could limit implementation (eg, use of off-label drugs)?
Comment: No. The recommended agents in the Bottom Line are FDA approved for the treatment of CRPC [castration-resistant
prostate cancer] in the described settings. However, my response would be “yes” to comments relative to “select” or “highly selected”
patients who may be offered bevacizumab or sunitinib, respectively, in which neither agent is FDA approved for the treatment of CRPC.







Comment: In general, no. The recommendations are sound and based on quality RCT [randomized controlled trial] evidence. I have
had a small population of patients (in whom this guideline would apply) decline some of these agents based on cost and/or co-pays and
sometimes based on their own perceptions of benefit. I do not see this circumstance being altered by the current set of guidelines. However,
the majority of patients with an acceptable PS [performance status] in whom I have this treatment discussion elect treatment and would
find this guideline helpful (but I still refer them to our financial navigator). The manuscript is very clear in having an open conversation
with patients regarding the harms and benefits of therapy and in a fashion consistent with shared decision making.
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13. Are the recommendation(s) sufficiently flexible to allow different patients (eg, comorbidities, ages) to receive care based on it?





Comment: The sections devoted to Qualifying Statements, Clinical Considerations, and Interpretation of Evidence provide
opportunities to have very practical and realistic guideline discussions with our patients. Within the various described treatment settings,
the GLIDES methodology and BRIDGE-Wiz software permit clarifying language relative to agent(s) that “should” or “may be” offered.
14. Are there particular recommendations for which you see large barriers to implementation?
Comment: No. Of the recommendations provided in the Bottom Line, I see no large barriers to implementation. For the comments
related to the use of bevacizumab or sunitinib in “select” or “highly selected” patients, I see large barriers within the United States as these
agents are not currently FDA approved for the treatment of CRPC.












17. Will this set of recommendations assist you in the care of your patients in your practice?





18. Please provide any additional comments you may have that were not addressed above.
Comment: Need to complete the sentence on bone modifying agents. Consider reconciling the comments related to the use of
bevacizumab and sunitinib in “select” and “highly selected” patient populations with the language used in the Bottom Line, which states
that neither of these agents should be offered.
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